EEG-based neurofeedback for ADHDprimary
2 projects
Both NEWROFEED (2015-2018) and KOALA FOCUS (2019) target ADHD and attention deficits using EEG-driven, drug-free therapeutic approaches.
Organization
MENSIA TECHNOLOGIES
French medtech SME building EEG-based personalized devices and digital therapeutics for ADHD and attention disorders, moving from clinical hardware to at-home e-health.
Technology SMEhealthFRSMENo active H2020 projects
H2020 projects
2
As coordinator
2
Total EC funding
€3.7M
Unique partners
0
What they do
Their core work
Mensia Technologies is a French medical technology SME that develops EEG-based diagnostic and therapeutic systems for attention disorders, especially ADHD. Their core offering combines personalized brain-signal biomarkers with neurofeedback training to deliver drug-free treatment. They have built both clinical-grade devices for hospital use and are extending that know-how into home-based e-health solutions. For businesses or clinicians, they are a specialist partner in neurotechnology and digital therapeutics for mental health.
Core expertise
What they specialise in
Personalized medical devicesprimary
1 project
NEWROFEED (EUR 3.6M) developed a personalized diagnostic and treatment device based on individual EEG biomarkers.
Home-based digital therapeuticssecondary
1 project
KOALA FOCUS explicitly targets at-home treatment of attention deficits, signaling a move toward consumer-facing e-health.
Clinical EEG biomarkerssecondary
1 project
NEWROFEED's core value proposition is translating EEG signal patterns into clinically actionable biomarkers for psychiatric diagnosis.
Evolution & trajectory
How they've shifted over time
Early focus
EEG-based ADHD medical device
Recent focus
At-home digital therapeutics for attention
Between 2015 and 2018, Mensia concentrated on NEWROFEED — a clinical-grade personalized medical device combining EEG diagnostics with neurofeedback therapy for ADHD, backed by a sizeable EUR 3.6M SME-2 grant. By 2019 they shifted toward KOALA FOCUS, a lighter SME-1 feasibility project reframing the same problem as a home-delivered, drug-free e-health service. The trajectory points from hospital-grade device development toward a scalable consumer digital therapeutic.
They are moving from regulated clinical hardware toward consumer-accessible home digital therapeutics — a good fit for partners in telemedicine, pediatric care, or health-insurance-backed behavioral interventions.
Collaboration profile
How they like to work
Role: consortium_leaderReach: European
Mensia operates as an independent SME coordinator rather than a consortium partner — both H2020 projects were single-beneficiary SME Instrument grants, meaning they ran the work in-house rather than through academic consortia. This is typical of a product-focused medtech company that owns its IP and commercializes directly. Partners working with them should expect a commercial counterpart, not a research lab.
Both H2020 grants were single-beneficiary SME Instrument projects, so no formal consortium partners are recorded. Their footprint is French-based with commercial ambitions across European markets.
Why partner with them
What sets them apart
Mensia is a rare European SME that has taken EEG-based neurofeedback for ADHD all the way from a EUR 3.6M clinical device project into a follow-up home-use e-health concept. Most neurotechnology players are either research spin-offs without a product or consumer wellness brands without clinical validation — Mensia sits between the two. For partners looking for a regulated, clinically-oriented counterpart in digital mental health, they offer an uncommon combination of medical device rigor and direct-to-patient ambition.
Notable projects
Highlights from their portfolio
- NEWROFEEDA EUR 3.6M SME-2 grant to bring a personalized EEG-based ADHD device to market — one of the larger single-beneficiary SME grants in digital health.
- KOALA FOCUSAn SME-1 feasibility study signaling a strategic pivot from clinical device to at-home, drug-free attention-training service.
Cross-sector capabilities
Digital health and e-health platformsMedical device software and regulationNeurotechnology and brain-computer interfacesPediatric health applications
More in Health & Biomedical
See all Health & Biomedical organizations →KOBENHAVNS UNIVERSITET
Denmark's largest research university, excelling in genomics, CRISPR, microbiome science, ancient DNA, and climate research across 696 H2020 projects.
Open →
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France's national biomedical research agency — 400+ H2020 projects spanning neuroscience, infectious disease, cancer, and omics-driven diagnostics.
Open →
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany's leading research university in molecular biosciences and translational medicine, with 303 H2020 projects and exceptional ERC grant concentration.
Open →